- November 15, 2023
- | Sernova
Women in Science: Cynthia Pussinen, CEO of Sernova on how her career was ‘written in the stars’
Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.
- November 15, 2023
- | Amolyt Pharma
Everybody Has a Thyroid… What Could Go Wrong??? Dr. Mark Sumeray, CMO of Amolyt Pharma
Dr. Mark Sumeray from Amolyt Pharma talks about their innovative approach to treating hormonal conditions. We’ll talk about two – when your parathyroid has been injured or removed, often during thyroid surgery, and another – when the pituitary starts overproducing growth hormone.
- November 8, 2023
- | Grifols
Overviewing Preliminary Data of ABvac40, a Vaccine for Alzheimer Disease: Jose Terencio
The vice president of Innovation and New Technologies at Grifols provided perspective on the interim phase 2 findings of ABvac40, a vaccine in development for patients with Alzheimer disease.
- November 8, 2023
- | Vittoria
Navigating the challenges of cell therapies
Vittoria’s innovative Senza5 platform, with its unique CD5-targeting approach, aims to enhance the efficacy, safety, and speed of cell therapies.
- November 6, 2023
- | CoRegen
The Legend Steve Gorlin’s Golden Rules
This week, the Business of Biotech sits down with the legendary biotech investor Steve Gorlin, now CEO of CoRegen, for a conversation on his golden rules for picking winners.
- November 3, 2023
- | eFFECTOR
Locks on Translation Initiation May Restrain Cancer
Effector Therapeutics is working on selective translation regulator inhibitors (STRIs).
- October 30, 2023
- | GigaGen
Can gene editing drive out HIV and hepatitis viruses from inside cells?
GigaGen, a subsidiary of Barcelona-based Grifols, aims to file an investigational new drug application next year, ahead of an initial trial of its recombinant polyclonal antibody therapy for chronic HBV infection
- October 30, 2023
- | GigaGen
Can gene editing drive out HIV and hepatitis viruses from inside cells?
GigaGen, a subsidiary of Barcelona-based Grifols, aims to file an investigational new drug application next year, ahead of an initial trial of its recombinant polyclonal antibody therapy for chronic HBV infection.